Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record.

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

Köhne, C-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., El-Serafi, M., Weiss, U., Burkhard, O., Rückle, H., Lichinitser, M., Langenbuch, T., Scheithauer, W., Baron, B., Couvreur, M.L., Schmoll, H.J.·2003·Journal of Clinical Oncology

Abstract

Purpose: This trial was conducted to determine whether high-dose fluorouracil (FU) given as a weekly 24-hour infusion is more active than bolus FU + leucovorin (LV), and whether high-dose infusional FU can be modulated by LV. Patients and Methods: A total of 497 patients with previously untreated metastatic colorectal cancer were randomly assigned to receive bolus FU 425 mg/m 2 intravenously + LV 20 mg/m 2 on days 1 to 5 and repeated on day 28 (FU + LV), or FU 2,600 mg/m 2 as a 24-hour infusion alone (FU 24h) or in combination with 500 mg/m 2 LV (FU 24h + LV)—all given weekly ×6 followed by a 2-week rest period. Survival was the major study end point. Results: With a median follow-up of more than 3 years, survival did not differ among the treatment groups (median FU + LV, 11.1 months [95% CI, 10.2 to 15.0 months]; FU 24h, 13.0 months [95% CI, 10.4 to 15.4 months]; FU 24h + LV, 13.7 months [95% CI, 12.0 to 16.4 months]; P = .724). Progression-free survival (PFS) was significantly longer for FU 24h + LV (median FU + LV, 4.0 months [95% CI, 3.4 to 4.9]; FU 24h, 4.1 months [95% CI, 3.4 to 5.0]; FU 24h + LV 5.6 months [95% CI, 4.4 to 6.7]; P = .029). The response rates in the subgroup of patients with measurable disease were 12%, 10%, and 17% for FU + LV, FU 24h, and FU 24h + LV, respectively (not significant). Occurrence of grade 3 and 4 diarrhea was higher in the FU 24h + LV arm (22%) compared with the FU 24h (6%) or FU + LV (9%) arms; however, stomatitis (11% in FU + LV v 3% in FU 24h v 5% in FU 24h + LV arms) and hematologic toxicity were higher in the bolus FU + LV arm. Global quality of life did not differ within the three arms. Conclusion: Neither FU 24h + LV nor FU 24h prolong survival, relative to bolus FU + LV. Leucovorin increases PFS if added to FU 24h, but increases toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2003.11.122

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 160

Metadata

Authors
Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., El-Serafi, M., Weiss, U., Burkhard, O., Rückle, H., Lichinitser, M., Langenbuch, T., Scheithauer, W., Baron, B., Couvreur, M. L., & Schmoll, H. J.
Venue
Journal of Clinical Oncology
Published
2003-10-15
Volume
21
Issue
20
Pages
3721-3728
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2115366398
Cited by
160
References
0
FWCI
9.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. https://app.cochat.ai/papers/10.1200/jco.2003.11.122
The paper
Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., El-Serafi, M., Weiss, U., Burkhard, O., Rückle, H., Lichinitser, M., Langenbuch, T., Scheithauer, W., Baron, B., Couvreur, M. L., & Schmoll, H. J. (2003). Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.11.122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.